EG226604 Inhibitors
Gm4847, with its predicted function as an N,N-dimethylaniline monooxygenase, plays a crucial role in cellular processes associated with xenobiotic metabolism. This enzymatic activity suggests involvement in the oxidation of N,N-dimethylaniline, a common substrate for monooxygenases. The ability of Gm4847 to enable N,N-dimethylaniline monooxygenase activity underscores its significance in the detoxification and modification of xenobiotics within the cell. As a key player in this metabolic pathway, Gm4847 contributes to the cellular defense against potentially harmful substances, reflecting the intricate network of enzymatic processes that ensure the maintenance of cellular homeostasis.
The inhibition of Gm4847 can be achieved through diverse mechanisms involving various chemical compounds. Direct inhibitors, such as those targeting specific cytochrome P450 enzymes (CYPs) like CYP3A4, CYP1A2, CYP2C9, and CYP2C19, interfere with the enzymatic activity of N,N-dimethylaniline monooxygenase. These inhibitors act by binding to and inhibiting the activity of these CYPs, thereby reducing Gm4847 activity and impacting its predicted function. Indirect inhibitors, such as monoamine oxidase (MAO) inhibitors, modulate Gm4847 through the regulation of MAO activity. By altering the levels of monoamines and influencing downstream pathways, MAO inhibitors indirectly affect Gm4847 expression and function. The inhibition of Gm4847 thus reveals a complex interplay of enzymatic regulation, highlighting potential points of intervention for understanding the molecular intricacies governing xenobiotic metabolism within the cellular environment. This exploration sheds light on the dynamic processes that safeguard cellular integrity by ensuring the effective and controlled metabolism of xenobiotics through the activity of enzymes like Gm4847.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole, a CYP3A4 inhibitor, directly influences Gm4847 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP3A4 by Ketoconazole leads to a reduction in Gm4847 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
5-Hydroxy Tryptophol | 154-02-9 | sc-217202 | 10 mg | $140.00 | 3 | |
5-Hydroxy Tryptophol, a MAO inhibitor, indirectly influences Gm4847 by modulating monoamine oxidase (MAO) activity. Inhibition of MAO by Tranylcypromine leads to changes in downstream pathways, influencing Gm4847 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine, a CYP1A2 inhibitor, directly influences Gm4847 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP1A2 by Fluvoxamine leads to a reduction in Gm4847 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine, a CYP2C9 inhibitor, directly influences Gm4847 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2C9 by Cimetidine leads to a reduction in Gm4847 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole, a CYP2C19 inhibitor, directly influences Gm4847 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2C19 by Fluconazole leads to a reduction in Gm4847 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Phenethyl-hydrazine | 51-71-8 | sc-331686 | 500 mg | $396.00 | ||
Phenethyl-hydrazine, a MAO inhibitor, indirectly influences Gm4847 by modulating monoamine oxidase (MAO) activity. Inhibition of MAO by Phenelzine leads to changes in downstream pathways, influencing Gm4847 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole, a CYP3A4 inhibitor, directly influences Gm4847 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP3A4 by Itraconazole leads to a reduction in Gm4847 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Rasagiline | 136236-51-6 | sc-204875 sc-204875A | 25 mg 100 mg | $101.00 $210.00 | ||
Rasagiline, a MAO inhibitor, indirectly influences Gm4847 by modulating monoamine oxidase (MAO) activity. Inhibition of MAO by Rasagiline leads to changes in downstream pathways, influencing Gm4847 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||